Change in FEV1 (mL) for FSC at Endpoint in Reversible/Non-Reversible patients

PLA SAL FP FSC250/50 PLA SAL FP FSC500/50

Pre-dose

Rev. -15 141 138 196 -1 132 123 191

Non-Rev. 19 26 74 126 -8 80 93 116

2 hrPost-dose

Rev. 46 262 179 328 29 287 161 319

Non-Rev. 71 119 107 221 28 175 111 195

SFCA3007

SFCA3006